ArticleScientific reports2017
Interleukin 17A as a good predictor of the severity of Mycoplasma pneumoniae pneumonia in children.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Innate and adaptive immunity pathways linking Mycoplasma pneumoniae to pediatric asthma phenotypes.European journal of pediatrics · 2026Review
- Early Risk Stratification for Subsequent Small Airway Dysfunction in Hospitalized Children withChildren (Basel, Switzerland) · 2026Article
- Role of Th17/Treg immune balance in assessment of mycoplasma pneumoniae pneumonia severity and its discriminatory value for asthma in children with mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Nasal delivery ofMicrobiology spectrum · 2026Article
- Dynamic multiplex cytokine profiling to identify risk factors for Lung Consolidation and Necrotizing Transformation in Children withMediterranean journal of hematology and infectious diseases · 2026Article
- Panoramic quantitative and visualization-based bibliometric analysis of Mycoplasma pneumoniae.Infection · 2025Article
- Combining circ_0054633 and clinical features to predict refractory Mycoplasma pneumoniae pneumonia in children.Scientific reports · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- The correlation between the level of cellular classification in bronchoalveolar lavage fluid of children with severe Mycoplasma pneumoniae and clinical characteristics.European journal of pediatrics · 2024Article
- Association of serum interleukin-17 level andTranslational pediatrics · 2024Article
- Serum inflammatory markers in children withWorld journal of clinical cases · 2024Article
- Peripheral blood microR-146a and microR-29c expression in children with Mycoplasma pneumoniae pneumonia and its clinical value.Italian journal of pediatrics · 2023Article
- Analysis of cytokine levels, cytological findings, and MP-DNA level in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia.Immunity, inflammation and disease · 2023Article
- The predictive values of soluble B7-DC in children with refractory mycoplasma pneumoniae pneumonia.Translational pediatrics · 2023Article
- Model-interpreted outcomes of artificial neural networks classifying immune biomarkers associated with severe infections in ICU.Frontiers in immunology · 2023Article
- Neutrophil-to-lymphocyte ratio as a predictor of poor outcomes ofFrontiers in immunology · 2023Article
- Risk Prediction Model for Necrotizing Pneumonia in Children withJournal of inflammation research · 2023Article
- B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs.NPJ vaccines · 2022Article
- Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2022Article
- A Lung Ultrasound-Based Nomogram for the Prediction of RefractoryInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early distinction between severe Mycoplasma pneumoniae pneumonia (MPP) and mild MPP is still difficult. The aim of this study was to analyze cytokines in bronchoalveolar lavage fluid (BALF) and explore predicting factors of severe MPP in children. Retrospective analysis was performed on 150 children with MPP or bronchial foreign body (FB) admitted in our hospital. The mRNA levels of IL17A were found significantly lower in severe MPP group comparing with mild MPP group or FB group. However, no significant difference was found in the levels of IL4, IL10 or interferon beta1 (IFNβ1) between the two groups. Receiver operator characteristic (ROC) curve analysis showed that IL17A can be used to distinguish severe MPP from mild MPP. These results were confirmed in a validation cohort including 40 MPP children from another hospital. IL17A levels were correlated with some clinical characters, such as refractoriness and pleural effusion. Lower IL17A levels were more likely to be found in refractory MPP children or in MPP children with pleural effusion. Moreover, the protein levels of IL17A in BALF were also found greatly decreased in children with severe MPP. Thus, decreased IL17A levels in BALF may be a valuable biomarker to identify severe MPP in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.